HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
XSSDvWBubY2pZE7K